Patent · US Active

Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity

US7919080B2 · kind B2 · utility

0Cited by
2References
4Claims
0Family size

Inventors

Key dates

Filing dateNov 13, 2007
Grant dateApr 5, 2011
Priority date
Expiry dateMay 3, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a cell line which can be substituted for β cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.